Zoledronic Acid (ZometaR) On Top Of Endocrine Therapy Boosts Survival In Premenopaus
 

The addition of zoledronic acid (ZometaR) to adjuvant endocrine therapy in premenopausal women with early breast cancer significantly reduces the risk of disease-free and recurrence-free survival events by about a third, according to results released at the 33rd Annual Congress of the European Society of Medical Oncology (ESMO.

More...